Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial

Article (PDF Available)inPEDIATRICS 123(1):301-12 · February 2009with143 Reads
DOI: 10.1542/peds.2007-3317 · Source: PubMed
Abstract
Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV; IPOL], and Haemophilus influenzae type b [Hib] vaccine [ActHIB]), when administered to infants and toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth (preschool) DTaP(5) dose. In this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of DTaP(5) coadministered with IPV and Hib vaccines or 1 lot of DTaP(5)-IPV-Hib combination vaccine. Subsequently, 849 of these study participants were given a fourth dose of DTaP(5) and Hib vaccines or a fourth dose of DTaP(5)-IPV-Hib at 1 to 16 months of age. Safety was monitored throughout the study, and blood specimens were obtained to assess antibody responses. DTaP(5)-IPV-Hib elicited similar or fewer solicited injection-site and systemic reactions as compared with the separate administration of US-licensed DTaP(5), IPV, and Hib vaccines. Seroresponse and seroprotection rates elicited by DTaP(5)-IPV-Hib were noninferior to US-licensed equivalent vaccines after the infant series and after the fourth dose. Children immunized with DTaP(5)-IPV-Hib had higher antibody geometric mean concentrations to pertussis toxoid and filamentous hemagglutinin; children immunized with the separate vaccines had higher responses to pertactin. Hib antibody responses to Hib polysaccharide were nearly identical in the DTaP(5)-IPV-Hib and separate-vaccine groups. Persistence of antibodies to the fifth (preschool) dose was also similar between groups. DTaP(5)-IPV-Hib combination vaccine was shown to be immunogenic and well tolerated. No clinically important differences in the safety or immunologic profiles were noted for DTaP(5)-IPV-Hib versus the separately administered, US-licensed equivalent vaccines. DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines.

Figures

DOI: 10.1542/peds.2007-3317
2009;123;301Pediatrics
Fernando R. Noriega
Fernando A. Guerra, Mark M. Blatter, David P. Greenberg, Michael Pichichero and
Clinical Trial
Persistence of Antibodies Before a Preschool Booster Dose: A Randomized,
Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and
Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate
http://pediatrics.aappublications.org/content/123/1/301.full.html
located on the World Wide Web at:
The online version of this article, along with updated information and services, is
of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2009 by the American Academy
published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point
publication, it has been published continuously since 1948. PEDIATRICS is owned,
PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly
at Indonesia:AAP Sponsored on June 4, 2013pediatrics.aappublications.orgDownloaded from
ARTICLE
Safety and Immunogenicity of a Pentavalent Vaccine
Compared With Separate Administration of Licensed
Equivalent Vaccines in US Infants and Toddlers and
Persistence of Antibodies Before a Preschool Booster
Dose: A Randomized, Clinical Trial
Fernando A. Guerra, MD, MPH
a,b
, Mark M. Blatter, MD
c
, David P. Greenberg, MD
d,e
, Michael Pichichero, MD
f,g
, Fernando R. Noriega, MD
e
,on
behalf of the Pentacel Study Group
a
Department of Public Health, San Antonio Metropolitan Health District, San Antonio, Texas;
b
Department of Pediatrics, University of Texas Health Science Center, San Antonio, Texas;
c
Primary Physicians Research, Pittsburgh, Pennsylvania ;
d
Department of Pediatrics, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania;
e
Sanofi Pasteur Inc, Swiftwater, Pennsylvania;
f
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York;
g
Elmwood Pediatrics, Rochester, New York
Financial Disclosure: Dr Guerra conducts clinical studies for Sanofi Pasteur, GlaxoSmithKline, Merck, and Novartis and is on the speaker’s bureau for Sanofi Pasteur, GlaxoSmithKline, and Merck; Dr Blatter
conducts clinical studies for Sanofi Pasteur, GlaxoSmithKline, Merck, Wyeth, and Novartis and is on the speaker’s bureau for Sanofi Pasteur